Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 3(3)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04591275Phase 3Completed

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

Role: lead

NCT04884399Phase 1Completed

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Role: lead

NCT03468790Phase 3Completed

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Role: lead

NCT03925051Phase 1Completed

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Role: lead

NCT03478111Phase 3Completed

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

Role: lead

NCT01550055Phase 2Completed

Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

Role: collaborator

All 6 trials loaded